Literature DB >> 25359562

mRNA transcript therapy.

Drew Weissman1.   

Abstract

mRNA is the central molecule of all forms of life. It is generally accepted that current life on Earth descended from an RNA world. mRNA, after its first therapeutic description in 1992, has recently come into increased focus as a method to deliver genetic information. The recent solution to the two main difficulties in using mRNA as a therapeutic, immune stimulation and potency, has provided the basis for a wide range of applications. While mRNA-based cancer immunotherapies have been in clinical trials for a few years, novel approaches; including, in vivo delivery of mRNA to replace or supplement proteins, mRNA-based generation of pluripotent stem cells, or genome engineering using mRNA-encoded meganucleases are beginning to be realized. This review presents the current state of mRNA drug technologies and potential applications, as well as discussing the challenges and prospects in mRNA development and drug discovery.

Entities:  

Keywords:  PKR; mRNA; modified nucleoside; pseudouridine; purification; therapeutic protein; vaccine

Mesh:

Substances:

Year:  2014        PMID: 25359562     DOI: 10.1586/14760584.2015.973859

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  49 in total

1.  Modified ARCA analogs providing enhanced translational properties of capped mRNAs.

Authors:  Ilona Kocmik; Karolina Piecyk; Magdalena Rudzinska; Anna Niedzwiecka; Edward Darzynkiewicz; Renata Grzela; Marzena Jankowska-Anyszka
Journal:  Cell Cycle       Date:  2018-08-17       Impact factor: 4.534

Review 2.  Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.

Authors:  Alvin J Mukalel; Rachel S Riley; Rui Zhang; Michael J Mitchell
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

Review 3.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

4.  Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.

Authors:  Mary G Prieve; Pierrot Harvie; Sean D Monahan; Debashish Roy; Allen G Li; Teri L Blevins; Amber E Paschal; Matt Waldheim; Eric C Bell; Anna Galperin; Jean-Rene Ella-Menye; Michael E Houston
Journal:  Mol Ther       Date:  2018-01-04       Impact factor: 11.454

Review 5.  Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.

Authors:  Zeljka Trepotec; Eva Lichtenegger; Christian Plank; Manish K Aneja; Carsten Rudolph
Journal:  Mol Ther       Date:  2018-12-22       Impact factor: 11.454

6.  A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery.

Authors:  Yuhang Jiang; Alice Gaudin; Junwei Zhang; Tushar Agarwal; Eric Song; Amy C Kauffman; Gregory T Tietjen; Yongheng Wang; Zhaozhong Jiang; Christopher J Cheng; W Mark Saltzman
Journal:  Biomaterials       Date:  2018-05-25       Impact factor: 12.479

7.  Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer.

Authors:  Chengxiang Zhang; Xinfu Zhang; Weiyu Zhao; Chunxi Zeng; Wenqing Li; Bin Li; Xiao Luo; Junan Li; Justin Jiang; Binbin Deng; David W McComb; Yizhou Dong
Journal:  Nano Res       Date:  2019-02-01       Impact factor: 8.897

8.  bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).

Authors:  Shuhui Lim; Regina Khoo; Khong Ming Peh; Jinkai Teo; Shih Chieh Chang; Simon Ng; Greg L Beilhartz; Roman A Melnyk; Charles W Johannes; Christopher J Brown; David P Lane; Brian Henry; Anthony W Partridge
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 9.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

10.  Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.

Authors:  Kevin J Kauffman; Faryal F Mir; Siddharth Jhunjhunwala; James C Kaczmarek; Juan E Hurtado; Jung H Yang; Matthew J Webber; Piotr S Kowalski; Michael W Heartlein; Frank DeRosa; Daniel G Anderson
Journal:  Biomaterials       Date:  2016-09-25       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.